Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa

Infection and Immunity

Volumn 72, Issue 11, 2004, Pages 6546-6553

  Arnold, Heinz ^a   Bumann, Dirk ^a,b   Felies, Melanie ^a   Gewecke, Britta ^a   Sörensen, Meike ^b   Gessner, J Engelbert ^a   Freihorst, Joachim ^a   Von Specht, Bernd Ulrich ^c   Baumann, Ulrich ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; OUTER MEMBRANE PROTEIN F; OUTER MEMBRANE PROTEIN I; SALMONELLOSIS VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; IMMUNOGENICITY; INFECTION RATE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT MUCOSA; SALMONELLA; SEROTYPE; STRAIN DIFFERENCE; VACCINATION; VIRUS EXPRESSION;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; HUMANS; IMMUNITY, MUCOSAL; LIPOPROTEINS; MALE; MICE; MICE, INBRED C57BL; PORINS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RECOMBINANT FUSION PROTEINS; RESPIRATORY MUCOSA; SALMONELLA TYPHIMURIUM; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 7044222885     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.72.11.6546-6553.2004     Document Type: Article

References (37)

1. Allen, J. S., G. Dougan, and R. A. Strugnell. 2000. Kinetics of the mucosal antibody secreting cell response and evidence of specific lymphocyte migration to the lung after oral immunisation with attenuated S. enterica var. typhimurium. FEMS Immunol. Med. Microbiol. 27:275-281.
2. c phenotype in Salmonella enterica serovar Typhimurium. Infect. Immun. 72:750-756.
3. Boucher, R. C. 2004. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur. Respir. J. 23:146-158.
4. Brennan, A. L., and D. M. Geddes. 2002. Cystic fibrosis. Curr. Opin. Infect. Dis. 15:175-182.
5. Bumann, D. 2001. In vivo visualization of bacterial colonization, antigen expression, and specific T-cell induction following oral administration of live recombinant Salmonella enterica serovar Typhimurium. Infect. Immun. 69:4618-4626.
6. +-T-cell responses. Infect. Immun. 69:7493-7500.
7. Bumann, D. 2002. Examination of Salmonella gene expression in an infected mammalian host using the green fluorescent protein and two-colour flow cytometry. Mol. Microbiol. 43:1269-1283.
8. Burns, J. L., R. L. Gibson, S. McNamara, D. Yim, J. Emerson, M. Rosenfeld, P. Hiatt, K. McCoy, R. Castile, A. L. Smith, and B. W. Ramsey. 2001. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J. Infect. Dis. 183:444-452.
9. Eckhardt, A., M. M. Heiss, W. Ehret, W. Permanetter, M. Duchene, H. Domdey, and B. U. von Specht. 1991. Evaluation of protective mAbs against Pseudomonas aeruginosa outer membrane protein I by C1q binding assay. Zentbl. Bakteriol. 275:100-111.
10. Fouts, T. R., A. L. DeVico, D. Y. Onyabe, M. T. Shata, K. C. Bagley, G. K. Lewis, and D. M. Hone. 2003. Progress toward the development of a bacterial vaccine vector that induces high-liter long-lived broadly neutralizing antibodies against HIV-1. FEMS Immunol. Med. Microbiol. 37:129-134.
11. Gabelsberger, J., B. Knapp, S. Bauersachs, U. I. Enz, B. U. von Specht, and H. Domdey. 1997. A hybrid outer membrane protein antigen for vaccination against Pseudomonas aeruginosa. Behring Inst. Mitt. 123:302-314.
12. Gilbert, P. B., Y. L. Chiu, M. Allen, D. N. Lawrence, C. Chapdu, H. Israel, D. Holman, M. C. Keefer, M. Wolff, and S. E. Frey. 2003. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored phase I and II clinical trials. Vaccine 21:2933-2947.
13. Göcke, K., U. Baumann, H. Hagemann, J. Gabelsberger, H. Hahn, J. Freihorst, and B. U. von Specht. 2003. Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule. FEMS Immunol. Med. Microbiol. 37:167-171.
14. Gomez-Duarte, O. G., B. Lucas, Z. X. Yan, K. Panthel, R. Haas, and T. F. Meyer. 1998. Protection of mice against gastric colonization by Helicobacter pylon by single oral dose immunization with attenuated Salmonella typhimurium producing urease subunits A and B. Vaccine 16:460-471.
15. Herremans, T. M., J. H. Reimerink, A. M. Buisman, T. G. Kimman, and M. P. Koopmans. 1999. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J. Immunol. 162:5011-5018.
16. Hohmann, E. L., C. A. Oletta, W. P. Loomis, and S. I. Miller. 1995. Macrophage-inducible expression of a model antigen in Salmonella typhimurium enhances immunogenicity. Proc. Natl. Acad. Sci. USA 92:2904-2908.
17. Hoiby, N. 2002. New antimicrobials in the management of cystic fibrosis. J. Antimicrob. Chemother. 49:235-238.
18. Hoiseth, S. K., and B. A. Stocker. 1981. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 291:238-239.
19. Jespersgaard, C., P. Zhang, G. Hajishengallis, M. W. Russell, and S. M. Michalek. 2001. Effect of attenuated Salmonella enterica serovar Typhimurium expressing a Streptococcus mutans antigen on secondary responses to the cloned protein. Infect. Immun. 69:6604-6611.
20. Johansen, H. K., H. P. Hougen, S. J. Cryz, Jr., J. Rygaard, and N. Hoiby. 1995. Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia in rats. Am. J. Respir. Crit. Care Med. 152:1337-1346.
21. Kunkel, E. J., and E. C. Butcher. 2003. Plasma-cell homing. Nat. Rev. Immunol. 3:822-829.
22. Larbig, M., E. Mansouri, J. Freihorst, B. Tümmler, G. Kohler, H. Domdey, B. Knapp, K. D. Hungerer, E. Hundt, J. Gabelsberger, and B. U. von Specht. 2001. Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Vaccine 19:2291-2297.
23. Londono-Arcila, P., D. Freeman, H. Kleanthous, A. M. O'Dowd, S. Lewis, A. K. Turner, E. L. Rees, T. J. Tibbitts, J. Greenwood, T. P. Monath, and M. J. Darsley. 2002. Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen. Infect. Immun. 70:5096-5106.
24. Mansouri, E., J. Gabelsberger, B. Knapp, E. Hundt, U. Lenz, K. D. Hungerer, H. E. J. Gilleland, J. Staczek, H. Domdey, and B. U. von Specht. 1999. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Infect. Immun. 67:1461-1470.
25. Metzger, W. G., E. Mansouri, M. Kronawitter, S. Diescher, M. Soerensen, R. Hurwitz, D. Bumann, T. Aebischer, B. U. von Specht, and T. F. Meyer. 2004. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 22:2273-2277.
26. Moser, C., P. O. Jensen, O. Kobayashi, H. P. Hougen, Z. Song, J. Rygaard, A. Kharazmi, and N. Hoiby. 2002. Improved outcome of chronic Pseudomonas aeruginosa lung infection is associated with induction of a Th1-dominated cytokine response. Clin. Exp. Immunol. 127:206-213.
27. Moser, C., H. K. Johansen, Z. Song, H. P. Hougen, J. Rygaard, and N. Hoiby. 1997. Chronic Pseudomonas aeruginosa lung infection is more severe in Th2 responding BALB/c mice compared to Th1 responding C3H/HeN mice. APMIS 105:838-842.
28. Moser, C., S. Kjaergaard, T. Pressler, A. Kharazmi, C. Koch, and N. Hoiby. 2000. The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type. APMIS 108:329-335.
29. Muszkat, M., A. B. Yehuda, M. H. Schein, Y. Friedlander, P. Naveh, E. Greenbaum, M. Schlesinger, R. Levy, Z. Zakay-Rones, and G. Friedman. 2000. Local and systemic immune response in community-dwelling elderly after intranasal or intramuscular immunization with inactivated influenza vaccine. J. Med. Virol. 61:100-106.
30. Pilette, C., Y. Ouadriri, V. Godding, J. P. Vaerman, and Y. Sibille. 2001. Lung mucosal immunity: immunoglobulin-A revisited. Eur. Respir. J. 18:571-588.
31. Quiding-Jabrink, M., I. Nordstrom, G. Granstrom, A. Kilander, M. Jertborn, E. C. Butcher, A. I. Lazarovits, J. Holmgren, and C. Czerkinsky. 1997. Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses. J. Clin. Investig. 99:1281-1286.
32. Rajan, S., and L. Saiman. 2002. Pulmonary infections in patients with cystic fibrosis. Semin. Respir. Infect. 17:47-56.
33. Rollenhagen, C., M. Sorensen, K. Rizos, R. Hurvitz, and D. Bumann. 2004. Antigen selection based on expression levels during infection facilitates vaccine development for an intracellular pathogen. Proc. Natl. Acad. Sci. USA 101:8739-8744.
34. Sirard, J. C., F. Niedergang, and J. P. Kraehenbuhl. 1999. Live attenuated Salmonella: a paradigm of mucosal vaccines. Immunol. Rev. 171:5-26.
35. Stevens, T. L., A. Bossie, V. M. Sanders, R. Fernandez-Botran, R. L. Coffman, T. R. Mosmann, and E. S. Vitetta. 1988. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 334:255-258.
36. Walsh, E. E. 1994. Humoral, mucosal, and cellular immune response to topical immunization with a subunit respiratory syncytial virus vaccine. J. Infect. Dis. 170:345-350.
37. Ward, S. J., G. Douce, D. Figueiredo, G. Dougan, and B. W. Wren. 1999. Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. Infect. Immun. 67:2145-2152.